Ongoing Clinical Trials With BCMA-Directed Bispecific Antibodies
Clinicians must maintain awareness of the latest clinical trials ongoing in the management of multiple myeloma, including those of bispecific antibody therapies targeting BCMA.
Selected Clinical Studies of BCMA-Directed Bispecific Antibody Therapies in Multiple Myeloma
| Treatment | Title | Link |
| Linvoseltamab (REGN5458) | A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) (LINKER-MM8) | https://clinicaltrials.gov/study/NCT07428369 |
| A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant | https://clinicaltrials.gov/study/NCT06932562 | |
| A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments | https://clinicaltrials.gov/study/NCT05137054 | |
| A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide, and Dexamethasone for Adult Patients With Relapsed/Refractory Multiple Myeloma (LINKER-MM3) | https://clinicaltrials.gov/study/NCT05730036 | |
| A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment (LINKER-MM4) | https://clinicaltrials.gov/study/NCT05828511 | |
| A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (LINKER-MM5) | https://clinicaltrials.gov/study/NCT07222761 | |
| IMMUNOPLANT for Newly Diagnosed Multiple Myeloma (IMMUNOPLANT) | https://clinicaltrials.gov/study/NCT06376526 | |
| A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM) (LINKER-SMM2) | https://clinicaltrials.gov/study/NCT07393282 | |
| Elranatamab (PF-06863135) | MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma | https://clinicaltrials.gov/ct2/show/NCT05090566 |
| Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients (ElLen) | https://clinicaltrials.gov/study/NCT06918002 | |
| A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments (MAGNETISMM-5) | https://clinicaltrials.gov/ct2/show/NCT05020236 | |
| A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant (MagnetisMM-6) | https://clinicaltrials.gov/study/NCT05623020 | |
| Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (MagnetisMM-7) | https://clinicaltrials.gov/ct2/show/NCT05317416 | |
| Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma (FASTER) | https://clinicaltrials.gov/study/NCT06974786 | |
| MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | https://clinicaltrials.gov/study/NCT06152575 | |
| Etentamig (ABBV-383) | Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma (CERVINO) | https://clinicaltrials.gov/study/NCT06158841 |
| A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adults Participants With Relapsed/Refractory Multiple Myeloma | https://clinicaltrials.gov/study/NCT05259839 | |
| Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma | https://clinicaltrials.gov/study/NCT06223516 | |
| A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma | https://clinicaltrials.gov/study/NCT05650632 | |
| Teclistamab | A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-9) | https://clinicaltrials.gov/study/NCT05572515 |
| A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-3) | https://clinicaltrials.gov/study/NCT05083169 | |
| Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4) | https://clinicaltrials.gov/study/NCT05243797 | |
| Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma (IFM2021-01) | https://clinicaltrials.gov/study/NCT05572229 | |
| A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (MonumenTAL-6) | https://clinicaltrials.gov/study/NCT06208150 | |
| A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma (TRIlogy-4) | https://clinicaltrials.gov/study/NCT07258511 | |
| A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (TRIlogy-5) | https://clinicaltrials.gov/study/NCT07518186 | |
| Cevostamab | A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (CAMMA 1) | https://clinicaltrials.gov/study/NCT04910568 |
| Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) | https://clinicaltrials.gov/study/NCT03275103 | |
| A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma (CAMMA 2) | https://clinicaltrials.gov/study/NCT05535244 | |
| Cevostamab Following CAR T Cell Therapy for RRMM | https://clinicaltrials.gov/study/NCT05801939 | |
| A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) | https://clinicaltrials.gov/study/NCT05927571 |
ALL URLs accessed April 24, 2026
